RWA Wealth Partners LLC Cuts Position in Novo Nordisk A/S $NVO

RWA Wealth Partners LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 19.9% during the third quarter, HoldingsChannel reports. The firm owned 193,931 shares of the company’s stock after selling 48,129 shares during the period. RWA Wealth Partners LLC’s holdings in Novo Nordisk A/S were worth $10,761,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Jennison Associates LLC raised its position in shares of Novo Nordisk A/S by 0.3% during the 2nd quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after purchasing an additional 63,341 shares during the period. Loomis Sayles & Co. L P boosted its holdings in shares of Novo Nordisk A/S by 1.5% during the second quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock valued at $867,998,000 after acquiring an additional 187,789 shares during the period. Folketrygdfondet increased its holdings in shares of Novo Nordisk A/S by 1.2% in the 3rd quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after acquiring an additional 117,370 shares during the period. Sustainable Growth Advisers LP raised its stake in Novo Nordisk A/S by 11.7% during the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after acquiring an additional 649,390 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Novo Nordisk A/S by 0.8% in the second quarter. State Street Corp now owns 6,047,683 shares of the company’s stock valued at $418,231,000 after acquiring an additional 47,430 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $38.64 on Wednesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm has a market cap of $172.52 billion, a PE ratio of 11.13 and a beta of 0.67. Novo Nordisk A/S has a twelve month low of $38.36 and a twelve month high of $93.80. The firm’s 50 day moving average price is $53.35 and its 200 day moving average price is $53.14.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is currently 23.63%.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Positive pipeline readout — a China Phase‑2 trial of triple‑agonist UBT251 (GLP‑1/GIP/glucagon) showed up to 19.7% mean weight loss at 24 weeks, highlighting diversification beyond semaglutide and a potential growth pillar if further trials confirm efficacy. Read More.
• Neutral Sentiment: Strategic/operational profiling — a ResearchAndMarkets/enterprise‑tech profile highlights Novo’s digital transformation and tech initiatives; useful context for long‑term efficiency but unlikely to move stock short‑term. Read More.
• Negative Sentiment: Phase‑III setback — CagriSema failed to demonstrate non‑inferiority to Lilly’s tirzepatide in REDEFINE‑4, directly triggering investor panic about Novo’s ability to defend obesity market share. Read More.
• Negative Sentiment: Price cuts announced — Novo said it will cut U.S. list prices for Ozempic and Wegovy (up to ~50% for Wegovy) starting 2027 to improve access, a move the market views as margin/revenue negative given the drugs’ current sales scale. Read More.
• Negative Sentiment: Analyst downgrades & sell‑side reassessment — Deutsche Bank, Kepler and others have cut ratings/targets after the trial news, accelerating selling and downward re‑pricing of NVO. Read More.
• Negative Sentiment: Legal/investor scrutiny — law firms have initiated investor‑suit outreach, adding headline risk and potential distraction. Read More.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on NVO shares. Citigroup began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 27th. They set a “neutral” rating for the company. CICC Research assumed coverage on Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective for the company. Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a report on Tuesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday. Finally, HSBC restated a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Six analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average target price of $56.07.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.